Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Intravenous bisphosphonates

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract Objectives: Skeletal-related events (SREs), i.e. pathologic fractures, spinal cord compression, surgery and radiation to… Expand
Is this relevant?
2019
2019
Abstract Background Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal… Expand
Is this relevant?
Review
2019
Review
2019
INTRODUCTION Intravenous bisphosphonates (IV BP) have been used to treat children with osteoporosis for many years. Favorable… Expand
Is this relevant?
2015
2015
The renal status of patients with bone metastases secondary to solid tumors and their treatment with nephrotoxic agents is not… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
OBJECTIVES To analyze whether oxidative stress (OS) changes are present in patients with bisphosphonate-related osteonecrosis of… Expand
Is this relevant?
2014
2014
PurposeThree bone-targeted agents (BTAs) are approved in the USA for prevention of bone complications among solid tumor patients… Expand
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2013
2013
PurposeCancer patients with bone metastases (BMets) are predisposed to skeletal complications. Bone-targeted therapies such as… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Atypical femur fractures represent a potential complication of chronic oral bisphosphonate therapy in women with… Expand
Is this relevant?
2011
2011
PURPOSE The etiology of osteonecrosis of the jaw is poorly understood, but preferential mandibular uptake of intravenous… Expand
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor-kappaB ligand, suppresses bone… Expand
Is this relevant?